Peptic ulcer esophagogastroduodenoscopy
Peptic ulcer Microchapters |
Diagnosis |
---|
Treatment |
Surgery |
Case Studies |
2017 ACG Guidelines for Peptic Ulcer Disease |
Guidelines for the Indications to Test for, and to Treat, H. pylori Infection |
Guidlines for factors that predict the successful eradication when treating H. pylori infection |
Guidelines to document H. pylori antimicrobial resistance in the North America |
Guidelines for evaluation and testing of H. pylori antibiotic resistance |
Guidelines for when to test for treatment success after H. pylori eradication therapy |
Guidelines for penicillin allergy in patients with H. pylori infection |
Peptic ulcer esophagogastroduodenoscopy On the Web |
American Roentgen Ray Society Images of Peptic ulcer esophagogastroduodenoscopy |
Risk calculators and risk factors for Peptic ulcer esophagogastroduodenoscopy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Peptic ulcer esophagogastroduodenoscopy
American College of Gastroenterology (ACG) guidelines 2017 for the treatment of H pylori infection (HPI) include the following recommendations for testing for H pylori :
- Active or past history of peptic ulcer disease.
- Low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma
- Confirmed history of PUD (not previously treated for H. pylori)
- Long-term therapy with nonsteroidal anti-inflammatory agents (NSAIDs) and low-dose aspirin
- Unexplained iron deficiency anemia following standard workup
- Idiopathic thrombocytopenic purpura
Algorithm for the Approach to Dyspepsia
Age ≥ 55 or ⊕ alarm features? | |||||||||||||||||||||||||||||||||||||
YES | NO | ||||||||||||||||||||||||||||||||||||
Endoscopy | H. pylori prevalence? | ||||||||||||||||||||||||||||||||||||
High | Low | ||||||||||||||||||||||||||||||||||||
Test-and-treat strategy ± acid suppression | Acid suppression trial | ||||||||||||||||||||||||||||||||||||
If eradication therapy is indicated | |||||||||||||||||||||||||||||||||||||
Clarithromycin resistance ≥ 20% | Clarithromycin resistance < 20% | ||||||||||||||||||||||||||||||||||||
Quadruple or sequential therapy | PCA or PCM or Bismuth quadruple therapy | ||||||||||||||||||||||||||||||||||||
PLA | Bismuth quadruple therapy or PLA | ||||||||||||||||||||||||||||||||||||
Adjust Rx per susceptibility test | |||||||||||||||||||||||||||||||||||||
Consider endoscopy if treatment fails | |||||||||||||||||||||||||||||||||||||